circRNA Dysfunction Restoration Therapy

Migration, Crosslink

📖

circRNA Dysfunction Restoration Therapy

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-circrna-dysfunction-re

📖 Wiki Page

therapeutic999 wordssynced 2026-04-02

circRNA Dysfunction Restoration Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">circRNA Dysfunction Restoration Therapy</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Novelty</td>
<td>9</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8</td>
</tr>
<tr>
<td class="label">Root-Cause Coverage</td>
<td>7</td>
</tr>
<tr>
<td class="label">Delivery Feasibility</td>
<td>5</td>
</tr>
<tr>
<td class="label">Safety Plausibility</td>
<td>6</td>
</tr>
<tr>
<td class="label">Combinability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Biomarker Availability</td>
<td>7</td>
</tr>
<tr>
<td class="label">De-risking Path</td>
<td>6</td>
</tr>
<tr>
<td class="label">Multi-disease Potential</td>
<td>8</td>
</tr>
<tr>
<td class="label">Patient Impact</td>
<td>7</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Priority</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>High</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>High</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Company/Group</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Ionis Pharmaceuticals</td>
<td>ASO platform</td>
</tr>
<tr>
<td class="label">Avid Radiopharmaceuticals<

...

circRNA Dysfunction Restoration Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">circRNA Dysfunction Restoration Therapy</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Novelty</td>
<td>9</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8</td>
</tr>
<tr>
<td class="label">Root-Cause Coverage</td>
<td>7</td>
</tr>
<tr>
<td class="label">Delivery Feasibility</td>
<td>5</td>
</tr>
<tr>
<td class="label">Safety Plausibility</td>
<td>6</td>
</tr>
<tr>
<td class="label">Combinability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Biomarker Availability</td>
<td>7</td>
</tr>
<tr>
<td class="label">De-risking Path</td>
<td>6</td>
</tr>
<tr>
<td class="label">Multi-disease Potential</td>
<td>8</td>
</tr>
<tr>
<td class="label">Patient Impact</td>
<td>7</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Priority</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>High</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>High</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Company/Group</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Ionis Pharmaceuticals</td>
<td>ASO platform</td>
</tr>
<tr>
<td class="label">Avid Radiopharmaceuticals</td>
<td>circRNA biomarkers</td>
</tr>
<tr>
<td class="label">Academic consortia</td>
<td>circRNA atlases</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Mitigation</td>
</tr>
<tr>
<td class="label">Delivery to CNS</td>
<td>Use intrathecal or AAV9-mediated delivery</td>
</tr>
<tr>
<td class="label">Off-target effects</td>
<td>Engineer high-specificity ASOs</td>
</tr>
<tr>
<td class="label">Variable circRNA expression</td>
<td>Patient stratification by biomarker signature</td>
</tr>
<tr>
<td class="label">Immune response to viral vectors</td>
<td>Use non-immunogenic delivery systems</td>
</tr>
<tr>
<td class="label">Scenario</td>
<td>Probability</td>
</tr>
<tr>
<td class="label">Best case</td>
<td>15%</td>
</tr>
<tr>
<td class="label">Base case</td>
<td>50%</td>
</tr>
<tr>
<td class="label">Conservative</td>
<td>25%</td>
</tr>
<tr>
<td class="label">Failure</td>
<td>10%</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

This therapeutic concept targets the restoration of circular RNA (circRNA) function in neurodegenerative diseases. CircRNAs are abundant in the brain, highly stable, and play critical roles in synaptic function, protein translation, and gene regulation. Their dysregulation contributes to amyloid metabolism, [tau](/proteins/tau) pathology, [alpha-synuclein](/proteins/alpha-synuclein) regulation, and synaptic dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS).

Therapeutic Rationale

Disease Context

CircRNAs are covalently closed loop structures lacking 5' caps and 3' poly(A) tails, conferring high stability in brain tissue. In neurodegeneration:

Alzheimer's Disease: Global downregulation of circRNAs in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex); circAPP upregulation contributes to amyloid pathology; circHIPK2 and circMAPT affect tau phosphorylation and synaptic plasticity[@circular2023][@synaptic2023].
Parkinson's Disease: circSNCA upregulation sequesters miR-7 and miR-153, leading to increased alpha-synuclein production; mitochondrial dysfunction-associated circRNAs are differentially expressed[@circsncamediated2023].
ALS: circRNAs derived from [TDP-43](/mechanisms/tdp-43-proteinopathy)-regulated genes show altered expression; loss of TDP-43 function affects circRNA biogenesis, creating a feed-forward pathological loop[@tdp2024].

Mechanism of Action

The therapeutic approach restores circRNA function through:

ASO-mediated circRNA restoration: Antisense oligonucleotides designed to promote back-splicing of specific neuroprotective circRNAs[5]

MiRNA sponge replacement: Engineered circRNA mimics that restore miRNA sequestration capacity

Gene therapy delivery: AAV vectors carrying circRNA expression cassettes[6]

10-Dimension Scoring

Total Score: 71/100

Target Indications

Development Pathway

Preclinical (Years 1-2)

Target Identification: Prioritize circRNAs with strongest disease-correlation (circMAPT, circSNCA, circHIPK2)

ASO Design: Develop back-splicing modulators using high-throughput screening

In vitro Validation: Test in iPSC-derived neurons from AD/PD patients

Animal Studies: Evaluate delivery, efficacy, and toxicity in mouse models

Clinical (Years 3-5)

Phase 1: Safety in healthy volunteers; biomarker correlation

Phase 2: Dose-finding in early-stage AD/PD patients

Phase 3: Efficacy endpoints with biomarker readouts

Competitive Landscape

Risks and Mitigation

Regulatory Considerations

ASO pathway established (e.g., Spinraza, Teplizumab)
Biomarker-driven development possible under FDA/EMA accelerated pathways
Orphan drug designation potential for rare ALS/FTD subtypes

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Actionable Next Steps

Lab Experiments

Clinical Protocol

[^

I### Phase 1: Target Validation & ASO Development (Mon- Budget: $3.5-5.5M

**Mile - Month 6: Complete circRNA profiling in 50 patient iPSC lines (AD/P - Month 9: Identify 3 l - Month 12: Design - Month

Phase 2: Preclinical Development (Months 15-30)

Budget: $10-18M
Milestones:
Month 21: IND-enabling studies complete
Month 24: Pre-IND meeting with FDA; biomarker validation
Month 27: IND filing
Month 30: Phase 1 ready

Phase 3: Clinical Development (Months 30-54)

Budget: $40-65M
Milestones:
Month 34: Phase 1a SAD complete (24 subjects)
Month 40: Phase 1b MAD complete (48 subjects), dose selection
Month 46: Phase 2 initiated (150 subjects)
Month 54: Phase 2 complete; efficacy signal assessment

Total Program Cost: $53.5-88.5M over 54 months

Risk-Adjusted Scenarios

Key Decision Gates

Academic & Industry Partners

Academic: Dr. Sebastian Kadener (Harvard) - circRNA biogenesis; Dr. Jan L. van Deutekom (Leiden) - ASO design
Industry: Ionis Pharmaceuticals, Roche CNS, Circio Holdings
Foundations: Alzheimer's Association, Michael J. Fox Foundation, ALS Association

Circular RN- RNA Metab- Synaptic Dysfunction in Neurodegeneration
Non-Coding RNAs in Neurodegeneration
[SNCA Gene](/genes/snca)
APP Gene
[MAPT Gene](/genes/mapt)

References

[Unknown, Circular RNAs in Alzheimer's Disease: From Bench to Bedside (2023) (2023)](https://doi.org/10.1007/s12035-023-03456-w)

[Unknown, Synaptic Circular RNAs: Implications for Neurodegenerative Diseases (2023) (2023)](https://doi.org/10.1007/s00401-023-02568-4)

[Unknown, circSNCA-mediated Pathogenesis in Parkinson's Disease (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105890)

[Unknown, TDP-43 and Circular RNAs in Amyotrophic Lateral Sclerosis (2024) (2024)](https://doi.org/10.1093/brain/awaa123)

[Unknown, CircRNA-based Therapeutics for Neurological Disorders (2024) (2024)](https://doi.org/10.1038/s41582-024-00890-8)

[Unknown, Biogenesis and Function of Circular RNAs in the Mammalian Brain (2022) (2022)](https://doi.org/10.1038/s41583-022-00567-8)

📖 View canonical wiki page →

Related Entities

therapeutics-circrna-dysfunction-restoration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-circrna-dysfunction-restoration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-22d9553370cf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-circrna-dysfunction-restoration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

219

Outgoing

238

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

circRNA Dysfunction Restoration Therapy

circRNA Dysfunction Restoration Therapy

circRNA Dysfunction Restoration Therapy

Overview

Therapeutic Rationale

Disease Context

Mechanism of Action

10-Dimension Scoring

Target Indications

Development Pathway

Preclinical (Years 1-2)

Clinical (Years 3-5)

Competitive Landscape

Risks and Mitigation

Regulatory Considerations

See Also

External Links

Actionable Next Steps

Lab Experiments

Clinical Protocol

I### Phase 1: Target Validation & ASO Development (Mon- Budget: $3.5-5.5M

Phase 2: Preclinical Development (Months 15-30)

Phase 3: Clinical Development (Months 30-54)

Total Program Cost: $53.5-88.5M over 54 months

Risk-Adjusted Scenarios

Key Decision Gates

Academic & Industry Partners

References

💬 Discussion

📗 Cite This Artifact

circRNA Dysfunction Restoration Therapy

circRNA Dysfunction Restoration Therapy

circRNA Dysfunction Restoration Therapy

Overview

Therapeutic Rationale

Disease Context

Mechanism of Action

10-Dimension Scoring

Target Indications

Development Pathway

Preclinical (Years 1-2)

Clinical (Years 3-5)

Competitive Landscape

Risks and Mitigation

Regulatory Considerations

See Also

External Links

Actionable Next Steps

Lab Experiments

Clinical Protocol

I### Phase 1: Target Validation & ASO Development (Mon- Budget: $3.5-5.5M

Phase 2: Preclinical Development (Months 15-30)

Phase 3: Clinical Development (Months 30-54)

Total Program Cost: $53.5-88.5M over 54 months

Risk-Adjusted Scenarios

Key Decision Gates

Academic & Industry Partners

Related Pages

References

💬 Discussion